title: Cationic lipid structure and formulation considerations for optimal gene transfection of the lung.
abstract: Enhanced gene transduction to the lung using cationic lipids could be attained through optimization of the structure of the lipids and the formulation of the cationic lipid:plasmid DNA (pDNA) complexes. We have expanded on our earlier observation of the importance of the structural orientation of the cationic lipid headgroup. Through the synthesis of a number of matched pairs of cationic lipids differing only in the configuration of their headgroup, we confirmed that those harboring a T-shape headgroup are more active than their linear counterparts, at least when tested in the lungs of BALB/c mice. Additionally, we demonstrated that not only are the structural considerations of these cationic lipids important, but also their protonation state, the free base being invariably more active than its salt counterpart. The salt forms of cationic lipids bound pDNA with greater avidity, which may have affected their subsequent intracellular dissolution and transit of the pDNA to the nucleus. Inclusion of a number of frequently used solutes in the vehicle severely inhibited the gene transfection activity of the cationic lipids. The selection of neutral co-lipids was also an important factor for overall transfection activity of the formulation, with significant gains in transfection activity realized when diphytanoylphosphatidylethanolamine or dilinoleoylphosphatidylethanolamine were used in lieu of dioleoylphosphatidylethanolamine. Finally, we showed that a transacylation reaction could occur between the cationic lipid and neutral co-lipid which reduced the transfection activity of the complexes. It is the hope that as our understanding of the many factors that influence the activity of these cationic lipid:pDNA complexes improves, formulations with much greater potency can be realized for use in the treatment of pulmonary diseases.
authors.affiliation: Genzyme Corporation, Framingham, MA 01701-9322, USA. john.marshall@genzyme.com
authors.forename: J
authors.initials: J
authors.lastname: Marshall
authors.forename: J B
authors.initials: JB
authors.lastname: Nietupski
authors.forename: E R
authors.initials: ER
authors.lastname: Lee
authors.forename: C S
authors.initials: CS
authors.lastname: Siegel
authors.forename: P W
authors.initials: PW
authors.lastname: Rafter
authors.forename: S A
authors.initials: SA
authors.lastname: Rudginsky
authors.forename: C D
authors.initials: CD
authors.lastname: Chang
authors.forename: S J
authors.initials: SJ
authors.lastname: Eastman
authors.forename: D J
authors.initials: DJ
authors.lastname: Harris
authors.forename: R K
authors.initials: RK
authors.lastname: Scheule
authors.forename: S H
authors.initials: SH
authors.lastname: Cheng
mesh_terms: D000818:Animals; D004355:Drug Stability; D005079:Excipients / Q000494:pharmacology; D005260:Female; D015316:Genetic Therapy; D008055:Lipids / Q000008:administration & dosage* / Q000737:chemistry; D008168:Lung / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D014162:Transfection
chemical_list: D005079:Excipients; D008055:Lipids